Spots Global Cancer Trial Database for advanced adult hepatocellular carcinoma
Every month we try and update this database with for advanced adult hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | NCT04497038 | Advanced Adult ... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | NCT01666756 | Adult Primary H... Advanced Adult ... Advanced Adult ... BCLC Stage B Ad... BCLC Stage C Ad... | Chinese herbal ... sorafenib tosyl... laboratory biom... pharmacological... | 18 Years - | City of Hope Medical Center | |
| Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma | NCT04576572 | Hepatocellular ... Liver Cancer Advanced Adult ... Cirrhosis, Live... Unresectable Li... Liver Transplan... | - | Inonu University | ||
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | NCT01488487 | Advanced Adult ... | Everolimus Pasireotide | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | NCT01010126 | Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino... | Bevacizumab Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma | NCT02418988 | Advanced Adult ... | TACE plus rAd-p... TACE | 18 Years - 80 Years | Shenzhen SiBiono GeneTech Co.,Ltd | |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | NCT04000737 | Advanced Hepato... | YIV-906+Sorafen... Placebo+Sorafen... | 18 Years - | Yiviva Inc. | |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer | NCT04022746 | Advanced Adult ... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... | Magnetic Resona... Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | NCT04497038 | Advanced Adult ... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02024087 | Advanced Adult ... | Dalantercept pl... | 18 Years - | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT01835223 | Advanced Adult ... Non-Resectable ... | Tivozanib (1mg) Tivozanib (1.5m... | 18 Years - | Roswell Park Cancer Institute | |
| Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma | NCT01777594 | Advanced Adult ... | G-202 | 18 Years - | GenSpera, Inc. | |
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | NCT02234986 | Advanced Adult ... Advanced Fibrol... | ENMD-2076 | 18 Years - 99 Years | CASI Pharmaceuticals, Inc. | |
| Noninvasive Surrogate Marker for Advanced Hepatocellular Carcinoma Response to Concurrent Chemoradiotherapy: MR Perfusion, Contrast Enhanced Ultrasound and Biomarkers | NCT01336452 | Advanced Adult ... | DCE MRI | 20 Years - | Yonsei University | |
| Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma | NCT01405573 | Advanced Adult ... | Best Supportive... sorafenib | 18 Years - | National Cancer Institute, Naples | |
| MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | NCT01425879 | Advanced Adult ... Localized Non-R... Recurrent Adult... Recurrent Gallb... Stage IV Distal... Stage IV Gallbl... Unresectable Ex... Unresectable Ga... | Akt Inhibitor M... Diagnostic Labo... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | NCT02042443 | Adult Cholangio... Advanced Adult ... BCLC Stage C Ad... BCLC Stage D Ad... Hilar Cholangio... Localized Non-R... Recurrent Adult... Recurrent Child... Recurrent Extra... Recurrent Gallb... Stage II Gallbl... Stage III Child... Stage IIIA Gall... Stage IIIB Gall... Stage IV Childh... Stage IV Distal... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | Capecitabine Fluorouracil Laboratory Biom... Leucovorin Calc... Trametinib | - | National Cancer Institute (NCI) | |
| Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | NCT01008566 | Adult Hepatocel... Advanced Adult ... Localized Non-R... Recurrent Adult... | Cixutumumab Laboratory Biom... Sorafenib Tosyl... | 19 Years - | National Cancer Institute (NCI) | |
| Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT02072486 | Advanced Adult ... Localized Non-R... Stage III Child... Stage IIIA Hepa... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Childh... Stage IVA Hepat... Stage IVB Hepat... | Laboratory Biom... Sorafenib Tosyl... | - | Roswell Park Cancer Institute | |
| MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | NCT02578602 | Adult Hepatocel... Advanced Adult ... BCLC Stage 0 Ad... BCLC Stage A Ad... BCLC Stage B Ad... BCLC Stage C Ad... BCLC Stage D Ad... Localized Non-R... Localized Resec... | Gadoxetate Diso... Magnetic Resona... | 18 Years - | University of Southern California | |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | NCT02042443 | Adult Cholangio... Advanced Adult ... BCLC Stage C Ad... BCLC Stage D Ad... Hilar Cholangio... Localized Non-R... Recurrent Adult... Recurrent Child... Recurrent Extra... Recurrent Gallb... Stage II Gallbl... Stage III Child... Stage IIIA Gall... Stage IIIB Gall... Stage IV Childh... Stage IV Distal... Stage IVA Gallb... Stage IVB Gallb... Unresectable Ex... | Capecitabine Fluorouracil Laboratory Biom... Leucovorin Calc... Trametinib | - | National Cancer Institute (NCI) | |
| Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT01899261 | Adult Hepatocel... Advanced Adult ... Localized Non-R... Recurrent Adult... | Stereotactic Ra... | 18 Years - | Albert Einstein College of Medicine | |
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | NCT02234986 | Advanced Adult ... Advanced Fibrol... | ENMD-2076 | 18 Years - 99 Years | CASI Pharmaceuticals, Inc. | |
| Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | NCT04497038 | Advanced Adult ... | Cabozantinib | 18 Years - | University of Michigan Rogel Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
